Could an asthma drug tame COPD Flare-Ups? new study investigates

NCT ID NCT05138250

Completed Disease control Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether mepolizumab, an asthma drug, can reduce lung inflammation and flare-ups in people with COPD who have high levels of eosinophils (a sign of asthma-like inflammation). Thirty-one participants received mepolizumab every 4 weeks for a year and had MRI scans to track changes in their lungs. The goal was to see if early reductions in inflammation led to fewer exacerbations and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mepolizumab
What this could lead to: If successful, this could show that mepolizumab reduces lung inflammation and flare-ups in a specific group of COPD patients, potentially leading to a new treatment option.
What could go wrong: This is a small pilot study with only 31 participants, so results may not apply to all COPD patients. The drug is already approved for asthma but may not work as well for COPD, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

Clinical Research Facility - NGH

Sheffield, S Yorkshire, S5 7AU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.